Faricimab


Generic Medicine Info
Indications and Dosage
Intravitreal
Neovascular (wet) age-related macular degeneration
Adult: Initially, 6 mg (0.05 mL) once every 4 weeks (approx every 28 days) for the 1st 4 doses. Assess disease activity 20 and/or 24 weeks after treatment initiation and individualise dosing frequency based on anatomic and/or visual outcomes. In patients without disease activity: 6 mg once every 16 weeks. In patients with disease activity: 6 mg once every 8 or 12 weeks. Discontinue treatment if visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment.

Intravitreal
Diabetic macular oedema
Adult: 6 mg (0.05 mL) once every 4 weeks (approx every 28 days) for the 1st 4 doses. Subsequent doses may be individualised using a treat-and-extend approach based on anatomic and/or visual outcomes. The treatment interval may be extended from every 4 to every 16 weeks, with extensions in increments of up to 4 weeks or reductions of up to 8-week intervals based on anatomic and/or visual outcomes. Alternatively, 6 mg (0.05 mL) once every 4 weeks for the 1st 6 doses, followed by 6 mg once every 8 weeks over the next 28 weeks. Discontinue treatment if visual and/or anatomic outcomes indicate that the patient is not benefitting from continued treatment.
Contraindications
Ocular or periocular infections, active intraocular inflammation, IOP ≥30 mmHg.
Special Precautions
Patient with poorly controlled glaucoma, risk factors for retinal pigment epithelial tears, high-risk proliferative diabetic retinopathy, active systemic infections. Diabetic patients with uncontrolled hypertension. Pregnancy and lactation.
Adverse Reactions
Significant: Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear, transient increases in IOP, arterial thromboembolic events, including stroke and MI.
Eye disorders: Cataract, conjunctival or vitreous haemorrhage, vitreous floaters, retinal pigment epithelial tear, increased lacrimation, uveitis, vitritis, increased lacrimation, eye pain, irritation or discomfort.
Intravitreal: Z (Avoid unless benefits outweigh risks.)
Patient Counseling Information
This drug may cause temporary visual disturbances, if affected, do not drive or operate machinery. Women of childbearing potential must use proven birth control methods during therapy and for at least 3 months after stopping the treatment.
Monitoring Parameters
Monitor IOP via tonometry and perfusion of the optic nerve head immediately following administration. Monitor for symptoms of endophthalmitis and retinal detachment (e.g. eye redness or pain, photophobia, blurred vision, other vision changes).
Action
Description:
Mechanism of Action: Faricimab, a recombinant humanised bispecific immunoglobulin G1 (IgG1) antibody, acts by dual inhibition of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). Inhibition of VEGF-A and Ang-2 leads to a reduction of vascular permeability and inflammation, inactivation of pathological angiogenesis and restoration of vascular stability.
Synonym: faricimab-svoa.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: Approx 2 days.
Metabolism: Expected to be catabolised in lysosomes to small peptides and amino acids.
Excretion: Estimated mean ocular and apparent systemic half-life: 7.5 days.
Storage
Store between 2-8°C. Do not freeze. Protect from light. May be stored between 20-25°C for up to 24 hours prior to use.
MIMS Class
Other Eye Preparations
ATC Classification
S01LA09 - faricimab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
References
Anon. Faricimab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 06/10/2022.

Anon. Faricimab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/10/2022.

Joint Formulary Committee. Faricimab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/10/2022.

Vabysmo 120 mg/mL (6 mg/0.05 mL) Solution for Injection (Roche Thailand Ltd., Bangkok). MIMS Thailand. http://www.mims.com/thailand. Accessed 06/10/2022.

Vabysmo 120 mg/mL Solution for Injection (Roche Products Limited). MHRA. https://products.mhra.gov.uk. Accessed 06/10/2022.

Vabysmo Injection, Solution (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/10/2022.

Disclaimer: This information is independently developed by MIMS based on Faricimab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in